CAMBRIDGE, MA – April 29, 2025 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company today announced its participation in the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4 in Philadelphia, PA.
The company will present compelling preclinical data on HFB100204, a novel CXCR5 depleting antibody for the treatment of I&I diseases. HFB100204 has shown potent and selective depletion of pathogenic CXCR5+ B and T follicular helper (Tfh) cells to prevent the production of autoantibodies against self-antigens, a key feature in many autoimmune conditions.
“Selective depletion of pathogenic immune cells provides a potentially effective and robust approach to address the underlying cause of many heterogeneous I&I diseases with high unmet needs such as Sjogren’s Disease,” said Francisco Adrian, Ph.D., Chief Scientific Officer of HiFiBiO Therapeutics. “When analyzing Sjögren’s disease patient samples using our Drug Intelligence Science (DIS®) platform, we found a significant correlation between certain clusters of pathogenic CXCR5+ B-cells and stages of disease severity. We are now translating these insights into our clinical development strategy.”
HiFiBiO’s novel immunotherapies and comprehensive translational platform demonstrate the company’s deep commitment to innovative research and the development of impactful therapies to address unmet medical needs.
Details of the poster presentation are as follows:
Title: CXCR5 as a Therapeutic Target in Autoimmune Diseases: Insights from Sjögren’s Disease.
Session Date: Friday, 2 May 2025
Session Time: 1:30 PM – 2:30 PM
Speaker: Jinping Gan, PhD, Head of Translational Medicine
The posters will be accessible on the HiFiBiO Therapeutics website following the live presentation.
About HFB100204
HFB100204 is a best-in-class Fc enhanced monoclonal antibody that depletes pathogenic CXCR5+ cells through ADCC while blocking CXCL13-dependent signaling. Dysregulated CXCL13 and/or CXCR5 expression and signaling have been associated with autoimmune and chronic inflammatory disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren’s Disease (SjD).
About Sjögren’s Disease (SjD)
Sjögren’s Disease is a chronic autoimmune disease in which autoantibodies attack exocrine glands, primarily those that produce saliva and tears, leading to dry mouth and dry eyes. The disorder can also affect joints, lungs, kidneys, skin, and nerves. There are currently no available disease-modifying treatment options for SjD. Based on published epidemiology literature, it is estimated there are more than 3 million people with SjD in the US. However, it is often underdiagnosed due to the disease’s non-specific symptoms and gradual onset.
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical-stage biotech driving a robust clinical pipeline of transformative immunotherapies targeting cancer and autoimmune diseases. HiFiBiO achieves an unprecedented understanding of immune modulation in human diseases by pioneering a unique high-resolution translational platform, Drug Intelligence Science (DIS®), which combines unique single-cell capabilities with AI/ML approaches. Using patient samples, DIS® enables the discovery of novel targets, effective antibody drugs, and predictive biomarkers to enhance the probability of success for immunotherapies. Moreover, HiFiBiO has established partnerships with major multinational pharmaceutical and biotech companies and has been recognized as one of the 2023 Fierce 15 biotech companies. For additional information, please visit www.hifibio.com
HiFiBiO® is a trademark of HiFiBiO Therapeutics and its affiliates